marked.bio

CLDN18.2 CAR-T · cell therapy

satricabtagene autoleucel

4 active trials, targeting Claudin 18.2. Not approved for any biomarker on marked.bio yet.

Also known as CT041, satri-cel.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
Claudin 18.2 expression 4 4 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of satricabtagene autoleucel.

  1. CARsgen Therapeutics 3

Trials

4 of 4 trials shown

  1. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

    Active, not recruiting Phase 1/2 CARsgen Therapeutics Started 2020Primary completion 2025-06 NCT04404595

    satricabtagene autoleucel

    Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay;

    Claudin 18.2 expressionGastric Cancer, Pancreatic Cancer

  2. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

    Active, not recruiting Phase 1/2 CARsgen Therapeutics Started 2020Primary completion 2024-10 NCT04581473

    satricabtagene autoleucelpaclitaxelirinotecanapatinib

    Phase Ib：Tumor tissue samples were positive for CLDN18.2 IHC staining； Phase II：Tumor tissue samples were positive for CLDN18.2 IHC staining and H…

    Claudin 18.2 expressionGastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma

  3. Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients

    Not yet recruiting Phase 1 Peking University Started 2025Primary completion 2027-06 NCT06857786

    satricabtagene autoleucel

    Must have CLDN18.2-positive tumor expression as determined by immunohistochemistry (IHC), defined as CLDN18.…

    Claudin 18.2 expressionGastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

  4. A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

    Recruiting Phase 1 CARsgen Therapeutics Started 2023Primary completion 2026-12 NCT05911217

    satricabtagene autoleucel

    Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive;

    Claudin 18.2 expressionPancreatic Cancer